Swiss Nuclides’ CHF 2.6 Million Series A Financing Round

Vischer assisted Swiss Nuclides in this transaction .

Swiss Nuclides AG, a developer of novel radionuclide PET tracers for the precision diagnostics, has raised CHF 2.6m from private investors.

The proceeds will be used to continue the preclinical and clinical develop of its lead molecules for prostate cancer, neuroendocrine tumours, and immunotherapy selection.

Swiss Nuclides is developing the PET tracers on a novel radionuclide production platform which enables the broad availability of these tracers while keeping the radiation burden on the patient to a minimum.

The Vischer team was led by Dr. Matthias Staehelin (Picture) with Dania Salvisberg.

Involved fees earner: Dania Salvisberg-Schneider – VISCHER AG; Matthias Staehelin – VISCHER AG;

Law Firms: VISCHER AG;

Clients: Swiss Nuclides AG;

Author: Federica Tiefenthaler